At the 2026 annual meeting of stockholders, Aprea Therapeutics, Inc. stockholders approved an amendment to the certificate of incorporation to authorize the Board of Directors to effect a reverse stock split of common stock at a ratio between one-for-three and one-for-eight. Aprea Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for patients with respiratory diseases.
